click enter text
full postview quarter covid boost
merck report financi result tuesday market open
compani broadli beat revenu ep howev lower
guidanc beat guidanc lower covid
bodi report full analysi
rate outperform among top pick among
inform stock cover see global
 march monthli controversi report us/eu
trade fundament data
upsid target
report limit sole use client wolf research pleas refer disclosur section locat end
report analyst certif import disclosur disclosur
page
tuesday open merck
report result beat us/consensu revenu ep covid boost
lower revenu ep guidanc due covid impact human anim health
saw share price close day modestli peer group averag
overal impress deliv solid result tuesday market open beat revenu
ep howev stand among peer least report result thu far compani
lower guidanc relat covid wherea other maintain guidanc even rais slightli
note simpli reflect heavi concentr product caregiver-administ
disrupt occur covid vaccin among product hardest hit anim health
weak go forward yet anoth contributor also note strong fx headwind compani
face uniqu pipelin littl new say view remain thin
note variou covid therapeut effort underway chang stanc rel compani
told us mid-march confer call head capit alloc note
paus share buyback retain liquid even though balanc sheet arguabl good shape alreadi
abund caution invari beg question whether final near
sort larger fill pipelin gap ask natur offer mani specif
investor long-wond what/when/who might acquir share realiti like
under-valued given durabl revenu ep stream across cours much next
decad least nearer-term stori may struggl variou competitor nip heel
keytruda rog tigit pipelin thin investor percept
depend keytruda on-going perform remain solid first loe essenti
start coupl lower guidanc like keep share price sidelin least
rate outperform among top pick among similarly-r name
inform stock cover see march monthli controversi
report us/eu pharma name
recent discuss pipelin manag see pipelin
revenu report sale vs consensu
non-gaap ep report vs consensu
keytruda sale vs consensu
januvia/janumet sale vs consensu
gardasil sale vs consensu
page
revenu vs prior
ep vs prior
capit alloc temporarili suspend share repurchas program continu invest
pipelin new materi news disclos
revenu decreas ep decreas
revenu estim chang ep estim chang
depend year
ep compound-annual-growth-rate ep compound-annual-growth-rate increas vs previou repres
above/below peer averag growth peer average compound-annual-growth-rate rate goe higher lower base
price target new price target vs prior repres unchang
multipl new lower ep estim
covid impact access mrk medicin impact mrk busi come mostli fact
major medicin heavili weight toward physician-administ product
portfolio mani pediatrician exampl delay vaccin physician often run
inventori gardisil pneumovax implanon nuvar bridion other among affect
product even oncologist delay start new therapi expect biggest impact
natur expect return pre-covid level anim health expect prolong impact
revenu guidanc lower due covid human health anim health fx
also take away opex declin low singl digit rate tax rate exp
unchang temporarili paus share repurchas activ yet say capit alloc
prioriti remain unchang remain firmli commit dividend still believ deliv
sustain long-term growth perspect much impact covid launch
 capit alloc main driver paus share repurchas better bu
dev opportun stop abund caution want make sure fund capital-expenditure
bu dev etc could reinstat repurchas see thing improv
page
 talk phase covid impact expect biggest neg impact vaccin
particular span infant adult oncolog expect impact
 talk payer mix shift advers way describ constitut us payer mix
commerci government keytruda larg portion part medicaid fairli
 one lower guidanc compani face similar headwind
suppli chain narrow less abl quickli adapt work homeset arent
bigger cost offset compani size reiter busi physician
administ quarter impact big health reduct littl half
fx also anim health mani co dont opex bring spend
doesnt want go harder opex doesnt realli see sustain demand-
driven issu instead temporari want continu invest busi investor
read anyth
 elabor currenc impact simpli carri forward see today
hedg currenc
 go back guidanc must see major impact lower guidanc
say ye see impact human health anim health
 high level talk broader impact rise unemploy busi
reiter exposur medicaid low shift toward program would smaller
 comment expans exposur say keytruda goe
grow slightli januvia also big
spent time talk variou covid initi despit say pipelin
unplug conf call march roger perlmutt said would pursu covid
therapeut describ vaccin initi optimist develop vaccin say
take measur thought approach guarante success near-term partli given
scale product
 comment novel covid platform vs go tradit approach
like call believ take time come vaccin work safe
reli time-proven techniqu believ may even take singl vaccin
tackl covid term passiv immun may role limit circumst
respond prior extended-dos regimen file soon
page
 seem us like rog tigit could problem compani roch smart
oncolog compani random data lung come part answer
talk tigit program made gener comment
keytruda strength work varieti pursu combin lenvima
believ good place compani answer question tigit program
 come back tigit hurdl push program quickli
tri optim say differ co differ perspect want see suffici
evid efficaci combin hold true program like want
absolut sure say doesnt enough data feel comfort yet tigit
 novel io agent investor watch close mention
tigit test first monotherapi
 opportun tmb-high patient popul point say benefit
certain set sought registr off-label use awar
gardasil vaccin
continu strength stock quarter pneumovax saw boost covid
 see vaccin busi return normal time frame expect infant
young children return first pneumovax adolesc young adult return
 convict reiter continu high convict cite balanc immun
respons across strain strength
 updat kra describ broader activ lot program
clinic
share
 uniqu lenvima chase aggress wherea other
especi context drug limit patent life mrk initi excit drug
monotherapi activ also see activ combin note everi multi-kinas
inhibitor differ
highlight profound trial mutat prostat cancer show os benefit
page
 updat time still expect chang
vericiguat w/bayer heart failur
 investor miss program enthusiasm seem low say victoria
studi includ patient mani trial exclud make brittl popul cite
public nejm present plenari present evid result actual
 investor miss program enthusiasm seem low remind
present result yet top-lin result talk chronic cough highli preval
condit said want dismiss challeng launch complet new area
page
exhibit show compani report actual result vs estim consensu
exhibit merck result vs wr estim consensu
page
exhibit summar financi guidanc vs estim
exhibit merck guidanc vs wr estim old new
page
newoldnewtot marginroughli expensesdecreas low singl digit rate guidancewr estim
exhibit captur chang forecast
exhibit chang wr model
page
exhibit show incom statement product revenu summari balanc sheet/cash flow
page
incom statement pharma anim oper incom income/ expens incom outstand margin total margin incom oper
page
exhibit wr merck balanc sheet cash flow statement
page
flow statement incom incom chang asset flow oper activ secur subsidiari sale secur subsidiari flow invest activ chang short-term treasuri paid flow financ activ exchang rate cash increas decreas cash sheet cash properti plant goodwil current term non-curr paid-in comprehens treasuri stock merck sharehold sharehold liabil sharehold
